MENLO PARK, Calif.,
Jan. 26, 2017 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, will share details of a new two-photon fluorescence
microscopy technique to visualize minocycline skin penetration
along with research that correlates the new visualization method
with the company's clinical data.
The research will be presented during two sessions at SPIE
Photonics West, the world's largest multidisciplinary event for
photonics, Jan. 28 and 29 in
San Francisco.
The two presentations are:
- "Visualization of drug distribution of topical minocycline in
human facial skin with fluorescence microscopy," at 11:40 a.m. on Jan. 28. BioPharmX Associate
Scientist Maiko Hermsmeier will
explain how, for the first time, BioPharmX was able to visualize
minocycline in human skin and the pilosebaceous unit by inducing
fluorescence in minocycline through a nonlinear optical approach
with two-photon excitation.
- "Optical microscopy of targeted drug delivery and local
distribution in skin of a topical minocycline," at 8:50 a.m. on Jan.
29. Kin F. Chan, executive vice president of research and
technology at BioPharmX, will discuss a potential practical
application for the newly developed process in guiding future
clinical trials using two-photon fluorescence microscopy.
The Photonics West event attracts more than 20,000 people to
hear the latest research and find the latest devices and systems
driving technology markets, including state-of-the art medical
technologies.
"It is always an honor to present new research to eminent
colleagues, but this is particularly exciting because we believe
our novel use of two-photon fluorescence microscopy may hold
significant potential for the medical and scientific communities
for translational research," said Kin F. Chan, executive vice
president of research and technology at BioPharmX. "We
believe it can be used to visualize and eventually quantify the
distribution of multiple drugs. This is important because it
promises a major advance to researchers working to optimize the
frequency, dosage and timing of topical drug treatments."
Chan's presentation will show how two-photon fluorescence
microscopy was used to confirm data from BioPharmX's BPX-01 Phase
2a clinical trial. The trial demonstrated that the company's unique
topical minocycline gel formulation delivered adequate minocycline
to the appropriate site to target P. acnes. Prior to
initiation of clinical studies, traditional fluorescence microscopy
technique and matrix-assisted laser desorption/ionization (MALDI)
were used to optimize the drug delivery system and to confirm
optimal treatment dose and timing of BPX-01. Traditional
fluorescence microscopy was limited in sensitivity while MALDI is
too costly and time-consuming for rapid optimization. The novel
multi-photon imaging approach has the potential to overcome both
deficiencies.
BPX-01[1] is the first and only stable hydrophilic
(non-oil-based) topical gel with fully solubilized minocycline that
can penetrate the skin to deliver the antibiotic to where acne
develops in the pilosebaceous unit. The company's studies are
designed to confirm whether BPX-01 can effectively treat acne with
lower, and potentially safer, dosages of the antibiotic.
BioPharmX recently announced the completion of enrollment in the
OPAL (tOPicAL Minocycline Gel) study – a Phase 2b dose-finding
clinical trial to assess the efficacy and safety of BPX-01 for the
treatment of acne vulgaris.
The 12-week, multi-center, randomized, double-blind, three-arm,
vehicle-controlled OPAL study involves 225 individuals, aged 9 to
40, who have moderate-to-severe inflammatory, non-nodular acne
vulgaris.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting 40 million to 50
million Americans. The U.S. market for acne medications is
estimated at $10 billion.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company that seeks to provide products through proprietary platform
technologies for prescription, over-the-counter and supplement
applications in dermatology and women's health. To learn more about
BioPharmX, visit
www.BioPharmX.com.
Forward-Looking Statement
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions and strategies,
including, but not limited to, statements regarding, whether BPX-01
can effectively treat acne with lower, and potentially safer,
dosages of the antibiotic, and whether the use of two-photon
fluorescence microscopy will be useful in guiding future clinical
trials, enable BioPharmX to visualize and eventually quantify the
distribution of multiple drugs, promote optimization of the
frequency, dosage and timing of topical drug treatments, and
overcome deficiencies in traditional fluorescence microscopy
including limitations in sensitivity, cost, and time. These
forward-looking statements may be identified by words such as
"plan", "expect," "anticipate," "believe," or similar expressions
that are intended to identify such forward-looking statements.
These forward-looking statements involve risks and uncertainties,
as well as assumptions, which, if they do not fully materialize or
prove incorrect, could cause our results to differ materially from
those expressed or implied by such forward-looking statements. The
risks and uncertainties include those described in the company's
filings with the Securities and Exchange Commission. Given these
risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
[1] Caution: BPX-01 is a new drug limited by federal (or
United States) law to
investigational use.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/spie-photonics-west-presentations-to-show-biopharmx-was-first-to-visualize-minocycline-on-the-skin-using-multiphoton-microscopy-300397139.html
SOURCE BioPharmX Corporation